Last reviewed 2026-04-23 · How we verify

Pramlintide and glucagon

This combination uses pramlintide to slow gastric emptying and suppress glucagon secretion, while glucagon provides a rapid-acting counter-regulatory hormone to prevent hypoglycemia.

This combination uses pramlintide to slow gastric emptying and suppress glucagon secretion, while glucagon provides a rapid-acting counter-regulatory hormone to prevent hypoglycemia. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Mechanism of action

Pramlintide is an amylin analog that modulates postprandial glucose excursions by delaying gastric emptying, suppressing glucagon secretion, and promoting satiety. Glucagon, a counter-regulatory hormone, rapidly raises blood glucose levels to prevent or treat hypoglycemic episodes. Together, this combination aims to improve glycemic control while reducing hypoglycemia risk in diabetes management.

Approved indications

• Type 1 diabetes mellitus
• Type 2 diabetes mellitus

Common side effects

• Nausea
• Hypoglycemia
• Injection site reactions
• Headache

Key clinical trials

• Glucagon Counterregulation in Type 1 Diabetes (NA)
• The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes (PHASE4)
• The Role of Amylin and Glucagon in T1DM (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pramlintide and glucagon CI brief — competitive landscape report
• Pramlintide and glucagon updates RSS · CI watch RSS
• Baylor College of Medicine portfolio CI